FDANews
FDAnews Drug Daily Bulletin

GOOD NEWS FOR HEART ATTACK SURVIVORS

Sept. 22, 2005

Novartis Pharmaceuticals Canada Inc. announced today that Health Canada has approved PrDiovan(*) (valsartan) for a new indication to reduce cardiovascular death in patients at high risk (with heart failure or left ventricular dysfunction) following a heart attack. Diovan(*) is the world's most prescribed angiotensin-receptor blocker (ARB) for mild-to-moderate hypertension. Currently, one in three patients who survives a heart attack will die within one year.

Canada NewsWire Group (http://www.newswire.ca/en/releases/archive/September2005/21/c2118.html)